The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The new facility offers an expanded laboratory alongside meeting areas dedicated to development meetings, formulation workshops, and brainstorming sessions
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The approval is backed by data showing deep, durable responses and manageable tolerability
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
Subscribe To Our Newsletter & Stay Updated
